SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation. SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects without suppressing the immune system, so that patients can achieve immune balance and live beyond their inflammation.

AP1189, our lead product selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression, unlike most anti-inflammatory drugs that suppress the body’s immune system by inhibiting key immune-signaling molecules. These traditional immunosuppression approaches can lead to opportunistic infections and other serious side effects.

The company is currently evaluating AP1189 in 2 Phase 2a clinical proof of concept (POC) trials in rheumatoid arthritis (RA), and in idiopathic membranous nephropathy (iMN, a form of nephrotic syndrome), both of which are expected to readout by year-end. SynAct recently completed a P2a POC trial in COVID-19 infected patients to speed the time to respiratory recovery and prevent severe respiratory insufficiency and the results were encouraging for further development.